Ionis Pharmaceuticals, Inc. has found its hopes of competing in the PCSK9 inhibitor field dashed as partner AstraZeneca plc has chosen not to move ION449 into Phase III development because it did not think it would be competitive against Novartis AG’s Leqvio (inclisiran).
Ionis announced on 23 September that the Phase IIb SOLANO study of ION449, also known as AZN8233, administered at 60mg had met its primary endpoint of achieving a statistically significant...